Clinical outcomes and molecular characteristics of lung-only and liver-only metastatic pancreatic cancer: results from a real-world evidence database

Abrahm Levi; Edik M. Blais; John Davelaar; Matthew Ebia; Angela Minasyan; Nima Nikravesh; Gillian Gresham; Lei Zheng; Jennifer Chuy; Rachna T. Shroff; Raymond Wadlow; Patricia DeArbeloa; Lynn M. Matrisian; Emmanuel Petricoin; Michael J. Pishvaian; Jun Gong; Andrew Hendifar; Arsen Osipov

doi:10.1093/oncolo/oyaf007

Abstract

Patients with lung-only mPDAC demonstrate an improved prognosis relative to those with liver-only mPDAC. Responses to chemotherapy do not explain these differences. Organotropic metastatic tumor diversity is mirrored at the molecular level in PDAC.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Levi et al. (2025) studied this question.

synapsesocial.com/papers/69d8bce452654bb436d19cef https://doi.org/10.1093/oncolo/oyaf007

View Full Paper

Ask AI

Bookmark

Share

Clinical outcomes and molecular characteristics of lung-only and liver-only metastatic pancreatic cancer: results from a real-world evidence database

Abstract

Discussion

Cite This Study

Clinical outcomes and molecular characteristics of lung-only and liver-only metastatic pancreatic cancer: results from a real-world evidence database

Abstract

Discussion

Cite This Study

Keep reading

Keep reading